The estimated Net Worth of Joshua T Brumm is at least $34.6 Milion dollars as of 8 March 2024. Mr Brumm owns over 429,730 units of Dyne Therapeutics stock worth over $17,538,735 and over the last 8 years he sold DYN stock worth over $16,266,955. In addition, he makes $789,444 as CEO a Pres & Director at Dyne Therapeutics.
Mr has made over 20 trades of the Dyne Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 429,730 units of DYN stock worth $11,125,710 on 8 March 2024.
The largest trade he's ever made was selling 429,730 units of Dyne Therapeutics stock on 8 March 2024 worth over $11,125,710. On average, Mr trades about 44,817 units every 83 days since 2016. As of 8 March 2024 he still owns at least 537,998 units of Dyne Therapeutics stock.
You can see the complete history of Mr Brumm stock trades at the bottom of the page.
Joshua T. Brumm is the CEO, Pres & Director at Dyne Therapeutics.
As the CEO a Pres & Director of Dyne Therapeutics, the total compensation of Mr Brumm at Dyne Therapeutics is $789,444. There are 2 executives at Dyne Therapeutics getting paid more, with Dewei Qiao having the highest compensation of $2,036,560.
Mr Brumm is 43, he's been the CEO a Pres & Director of Dyne Therapeutics since . There are 19 older and 5 younger executives at Dyne Therapeutics. The oldest executive at Dyne Therapeutics, Inc. is Yuezhou Ou, 68, who is the Independent Non-Executive Director.
Joshua's mailing address filed with the SEC is 1560 TRAPELO ROAD, , WALTHAM, MA, 02451.
Over the last 4 years, insiders at Dyne Therapeutics have traded over $197,573,300 worth of Dyne Therapeutics stock and bought 5,790,447 units worth $92,382,301 . The most active insiders traders include Capital Management, L.P.Kol..., Jason P Rhodes a Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $3,566,016. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth $68,914.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Dyne Therapeutics executives and other stock owners filed with the SEC include: